CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 
 

XFOR's Income from Cont. Operations Growth by Quarter and Year

X4 Pharmaceuticals Inc's Income from Cont. Operations results by quarter and year




XFOR Income from Cont. Operations (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - -2.31 -21.87 -20.18
III Quarter September - -55.71 -21.21 -19.64
II Quarter June - -24.02 -24.22 -26.92
I Quarter March -51.77 -29.10 -35.91 -18.40
FY   -51.77 -111.14 -103.21 -85.14



XFOR Income from Cont. Operations first quarter 2024 Y/Y Growth Comment
X4 Pharmaceuticals Inc in the first quarter 2024 recorded loss from continued operations of $ -51.77 millions.

According to the results reported in the first quarter 2024, X4 Pharmaceuticals Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While X4 Pharmaceuticals Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter 2024.




XFOR Income from Cont. Operations ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
X4 Pharmaceuticals Inc's first quarter 2024 Income from Cont. Operations $ -51.77 millions XFOR's Income Statement
X4 Pharmaceuticals Inc's first quarter 2023 Income from Cont. Operations $ -29.10 millions Quarterly XFOR's Income Statement
New: More XFOR's historic Income from Cont. Operations Growth >>


XFOR Income from Cont. Operations (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

X4 Pharmaceuticals Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2024 loss from continued operations of -51.77 millions by X4 Pharmaceuticals Inc look even less good if you take a look at -2.31 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While X4 Pharmaceuticals Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2024 loss from continued operations of -51.77 millions by X4 Pharmaceuticals Inc come out even more unfavourable considering the loss from continued operations -2.31 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While X4 Pharmaceuticals Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


X4 Pharmaceuticals Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -133.80 $ -111.14 $ -130.71 $ -96.21 $ -96.41
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
X4 Pharmaceuticals Inc' has realized cumulative trailing twelve months loss from continued operations of $ -134 millions in the Mar 31 2024 period.
The business is worsening as the cumulative loss from continued operations is becoming larger from $ -111.14 millions for the period from Sep 30 2023 to Dec 31 2022 and $ -103.22 millions for the twelve months ending in the quarter Dec 31 2022.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
X4 Pharmaceuticals Inc' has realized cumulative trailing twelve months loss from continued operations of $ -134 millions in the Mar 31 2024 period.
The results are detiriorating as the cumulative loss from continued operations is becoming larger from $ -111.14 millions in TTM ending quarter Sep 30 2023 and $ -103.22 millions for the twelve months ending in the quarter a year ago Jason Baker told.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
XFOR's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for XFOR's Competitors
Income from Cont. Operations Growth for X4 Pharmaceuticals Inc's Suppliers
Income from Cont. Operations Growth for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Dividend Payout Ratio
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2024
National Healthcare Corp132.62%$ 132.619 millions
Glucotrack Inc 127.60%$ 127.605 millions
Sotera Health Company122.48%$ 122.484 millions
Insulet Corporation116.39%$ 116.387 millions
Embecta Corp 106.43%$ 106.429 millions
Nature s Sunshine Products inc 98.72%$ 98.723 millions
Ligand Pharmaceuticals Incorporated97.50%$ 97.503 millions
Halozyme Therapeutics Inc 93.92%$ 93.924 millions
Davita Inc 79.28%$ 79.284 millions
Biomarin Pharmaceutical Inc74.35%$ 74.353 millions
Corcept Therapeutics Inc74.06%$ 74.062 millions
Carlisle Companies Incorporated71.59%$ 71.586 millions
Merck and Co Inc 68.74%$ 68.743 millions
Eli Lilly And Company66.77%$ 66.771 millions
Amphastar Pharmaceuticals Inc 65.86%$ 65.861 millions
Lemaitre Vascular Inc 63.69%$ 63.692 millions
Enzon Pharmaceuticals inc 62.44%$ 62.437 millions
Lifevantage Corp62.33%$ 62.329 millions
Vertex Pharmaceuticals Inc57.13%$ 57.131 millions
Boston Scientific Corporation57.01%$ 57.006 millions
Integer Holdings Corporation56.97%$ 56.969 millions
Intuitive Surgical Inc 51.72%$ 51.718 millions
Shockwave Medical Inc 41.46%$ 41.459 millions
Medpace Holdings Inc 40.74%$ 40.740 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com